2026-08-22 · mounjaro, zepbound, tirzepatide, glp-1, brand comparison, insurance, cost, SURMOUNT, SURPASS

Are Mounjaro and Zepbound the same drug?

Yes. Both are tirzepatide, manufactured by Eli Lilly, in identical single-dose weekly pens at the same six strengths (2.5, 5, 7.5, 10, 12.5, and 15 mg). The molecule, dose range, side-effect profile, and dose escalation schedule are all the same. What differs is the FDA-approved indication on the label — Mounjaro for type 2 diabetes, Zepbound for chronic weight management and moderate-to-severe obstructive sleep apnea in adults with obesity — and how insurance and cash-pay programs treat each brand.

Which is cheaper — Mounjaro or Zepbound?

In 2026, Zepbound is the cheaper cash-pay option because Eli Lilly's LillyDirect self-pay program sells Zepbound single-dose vials from roughly $349 to $649 per month depending on dose. Mounjaro has no equivalent direct-to-consumer vial program. Auto-injector pen list prices are close (Mounjaro ~$1,080/month, Zepbound ~$1,060/month), so with insurance the two are effectively interchangeable on price; without insurance, Zepbound via LillyDirect is materially cheaper.

Can I use Mounjaro for weight loss if I don't have diabetes?

Some clinicians prescribe Mounjaro off-label for weight loss when Zepbound is not covered, but insurance almost never covers off-label Mounjaro without a documented type 2 diabetes diagnosis. If your goal is weight loss and you do not have T2D, the on-label pathway is Zepbound. Either way you are taking the same molecule at the same dose — the choice is a coverage and access decision, not a clinical one.

Does Medicare cover Mounjaro or Zepbound?

Medicare Part D covers Mounjaro for type 2 diabetes with a documented HbA1c ≥6.5%. Medicare Part D does not cover Zepbound for weight loss alone — the federal Part D obesity-drug exclusion still stands in 2026. The December 2024 Zepbound label expansion for moderate-to-severe obstructive sleep apnea in adults with obesity is the narrow current lever for Part D coverage of Zepbound. For patients with neither T2D nor OSA, the LillyDirect vial program is the current lowest-friction pathway.

Can I switch from Mounjaro to Zepbound?

Yes, and the switch is dose-for-dose because the pens and molecule are identical: 5 mg Mounjaro equals 5 mg Zepbound, 15 mg equals 15 mg. Your prescriber writes for the new brand at the same numeric dose you were on and titration does not restart unless you have been off drug for more than about six weeks. Insurance step therapy may require a prior authorization for the change of brand, but not a re-titration.

Do Mounjaro and Zepbound have the same side effects?

Yes. Because the molecule is the same, the safety profile is identical: nausea (~25–30% at 15 mg), diarrhea (~15%), constipation (~10%), and vomiting (~10%), with side effects most pronounced during dose escalation. Both share the class boxed warning for thyroid C-cell tumors based on rodent data, and both carry the same uncommon-but-serious risks of pancreatitis, gallbladder disease, and dehydration-related acute kidney injury.

Is compounded tirzepatide still legal in 2026?

No. The FDA removed tirzepatide from its drug shortage list in October 2024, following resolution of Eli Lilly's Sixth Circuit litigation. That ended the legal basis for routine 503A compounding of tirzepatide, and the FDA now treats compounded tirzepatide as enforcement-priority illegal. Any product marketed as compounded tirzepatide in 2026 is either mislabeled, counterfeit, or being dispensed under a carve-out that no longer applies to this molecule.

Is Zepbound better than Wegovy?

By average weight loss, yes — SURMOUNT-1 showed roughly 21% mean weight loss on tirzepatide 15 mg over 72 weeks, versus about 15% on semaglutide 2.4 mg in STEP-1 over 68 weeks. SURMOUNT-5 later confirmed a head-to-head advantage for tirzepatide over semaglutide in adults with obesity. Zepbound also carries an FDA-approved indication for moderate-to-severe obstructive sleep apnea in adults with obesity, which Wegovy does not.

Mounjaro vs Zepbound

The one-sentence answer

Mounjaro and Zepbound are the same drug — tirzepatide, made by Eli Lilly — in the same pen at the same doses. The only real differences are the FDA-approved indication on the label, how insurance covers each brand, and — in some 2026 markets — the price you pay at the counter. This page compares Mounjaro and Zepbound directly for readers who already know they want tirzepatide and are trying to figure out which brand is the right pathway.

For the broader four-brand landscape (semaglutide plus tirzepatide), see GLP-1 medications compared. If you are still choosing between the semaglutide side and the tirzepatide side, start with semaglutide vs tirzepatide.

Same molecule — the FDA label difference

Both Mounjaro and Zepbound are tirzepatide, a once-weekly subcutaneous injection that activates two gut-hormone receptors — GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Both are manufactured by Eli Lilly and supplied in the same six single-dose pen strengths: 2.5, 5, 7.5, 10, 12.5, and 15 mg.

The difference is the FDA-approved indication.

• Mounjaro received FDA approval in May 2022 for adults with type 2 diabetes, on the strength of the SURPASS trial program. It is used alongside diet and exercise to improve glycemic control.
• Zepbound received FDA approval in November 2023 for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition, on the strength of the SURMOUNT-1 trial. In December 2024, the FDA expanded the Zepbound label to include moderate-to-severe obstructive sleep apnea in adults with obesity, based on the SURMOUNT-OSA trial — the first medication ever approved specifically for OSA in an obesity context.

The pens, the doses, the escalation schedule, and the safety profile are the same. What changes at the pharmacy counter is which indication is on the label and, therefore, which patients most plans will pay for.

Cost comparison — 2026 US retail and cash-pay

Cash prices for the auto-injector pens are almost identical. The real cost difference is the cash-pay vial route on the Zepbound side.

Zepbound is currently the cheaper cash-pay option because Mounjaro does not have an equivalent direct-to-consumer vial program in 2026. The LillyDirect Self-Pay Pharmacy program launched in 2024 and, as of 2026, still covers only Zepbound vials — not Mounjaro. Patients who need tirzepatide but do not have coverage typically end up on the LillyDirect Zepbound route regardless of whether their clinical indication would ordinarily point to Mounjaro.

One 2026 detail matters for both brands: the FDA tirzepatide compounding shortage carve-out ended in October 2024 after Eli Lilly’s Sixth Circuit litigation resolved in Lilly’s favor. 503A compounded tirzepatide is now FDA enforcement-priority illegal. That change is covered in more detail in the compounded semaglutide and tirzepatide safety pillar and in the GLP-1 cost and insurance guide.

Insurance coverage — the actual difference in 2026

Insurance coverage — not the molecule — is the largest practical difference between Mounjaro and Zepbound. The rules split cleanly by indication.

• Mounjaro is generally covered by commercial insurance and by Medicare Part D for adults with type 2 diabetes who have a documented HbA1c of ≥6.5%. Prior authorization is nearly universal but usually straightforward when the T2D diagnosis is on file.
• Zepbound is generally covered by commercial insurance for chronic weight management when a patient has a documented BMI ≥30, or ≥27 with a weight-related comorbidity (hypertension, dyslipidemia, sleep apnea, prediabetes). Coverage almost always requires prior authorization, BMI documentation, and often a documented lifestyle-intervention attempt.
• Zepbound is not covered by Medicare Part D for a weight-only indication under current 2026 federal rules. The Part D obesity-drug exclusion in the Social Security Act still applies. The December 2024 Zepbound label expansion for moderate-to-severe obstructive sleep apnea is the narrow lever Medicare beneficiaries can use to get Part D coverage of Zepbound in 2026 — but only with a documented OSA diagnosis meeting AHI criteria.

Practical translation:

• If you have type 2 diabetes and want tirzepatide, Mounjaro is your covered pathway — commercial or Medicare.
• If you have obesity without T2D and have commercial insurance, Zepbound is your covered pathway.
• If you have Medicare Part D and no T2D and no OSA, neither brand is covered for weight loss. LillyDirect Zepbound vials at $349–$649/month is the current lowest-friction workaround.

For a fuller cost and coverage walkthrough across all four major GLP-1 brands, see the GLP-1 cost and insurance pillar.

Effectiveness — no clinically meaningful difference

Head-to-head trials of Mounjaro versus Zepbound do not exist and would not be informative — the molecule is identical. What we have instead are the pivotal trials for each brand’s indication, which measured weight loss in different populations.

• SURMOUNT-1 (Jastreboff et al., NEJM, 2022; n = 2,539; 72 weeks): adults with obesity but without diabetes. Mean weight loss on tirzepatide 15 mg was approximately 21% of body weight. This is the label-supporting trial for Zepbound.
• SURPASS-3 (Ludvik et al., Lancet, 2021; n = 1,444; 52 weeks): adults with type 2 diabetes. Mean weight loss on tirzepatide 15 mg was approximately 12% of body weight, alongside an HbA1c reduction of roughly 2.4 percentage points. This is a representative T2D-context weight trial for Mounjaro.

The dose–response effect is identical because the molecule is identical. The observed difference in average weight loss between SURMOUNT-1 (weight-focused population, no T2D) and SURPASS-3 (T2D population) reflects a well-documented biological pattern: adults with type 2 diabetes lose approximately 30–40% less weight on incretin therapy than adults without diabetes at the same dose, at least in part because insulin resistance blunts the appetite-suppressing effect and baseline BMI often differs.

If you are still choosing between the semaglutide side and the tirzepatide side of the GLP-1 landscape, the semaglutide vs tirzepatide comparison covers the head-to-head SURPASS-2 and SURMOUNT-5 data. If you are choosing between weight-management brands specifically, this page (Mounjaro vs Zepbound) and the ozempic vs wegovy comparison together cover the four-corner brand-vs-brand grid.

Side effects — identical

Because the drug is the same, so is the side-effect profile. Common effects, roughly in order of frequency at the 15 mg dose:

• Nausea (~25–30%)
• Diarrhea (~15%)
• Constipation (~10%)
• Vomiting (~10%)
• Decreased appetite (~10%)
• Injection-site reactions and mild abdominal discomfort (less frequent)

Serious but uncommon risks are also shared:

• Boxed warning for thyroid C-cell tumors, based on rodent studies. No confirmed human medullary thyroid signal to date, but tirzepatide is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2).
• Pancreatitis (rare). Stop the drug and contact your clinician if you develop persistent, severe abdominal pain.
• Gallbladder disease (uncommon), particularly with rapid weight loss.
• Acute kidney injury (uncommon), usually secondary to dehydration from persistent vomiting or diarrhea.
• Diabetic retinopathy in patients with T2D — reported in the SURPASS program and to be monitored in patients with pre-existing retinopathy.
• Hypoglycemia risk when combined with insulin or sulfonylureas.

The Ozempic side effects pillar covers the class-wide GI titration profile in more depth; the same practical guidance (small, protein-forward meals, steady hydration, holding a dose an extra four weeks when a level is not tolerated) applies to both Mounjaro and Zepbound.

Switching between Mounjaro and Zepbound

Switching between the two brands is common. The usual triggers are:

• Insurance formulary changes — a plan drops coverage of one brand and adds the other.
• A new T2D diagnosis on Zepbound therapy — the covered brand becomes Mounjaro.
• Loss of a T2D diagnosis (rare, but possible after significant weight loss and diabetes remission) — the covered pathway shifts to Zepbound.
• Access disruption — one brand is temporarily unavailable at a preferred pharmacy.

The switch is dose-for-dose because the pen and the molecule are identical. If you were on 5 mg Mounjaro, your prescriber writes 5 mg Zepbound. If you were on 15 mg Zepbound, your prescriber writes 15 mg Mounjaro. Dose escalation does not restart unless you have been off drug for more than roughly six weeks; that gap is long enough that most clinicians re-titrate from a lower dose to re-establish tolerability.

Insurance step-therapy language may require a prior authorization for change of brand, but not for change of drug, because the drug is unchanged. Ask the prescribing clinic to run a benefits check before the switch so any PA can be pre-empted rather than caught at the pharmacy counter.

The compounded-tirzepatide situation in 2026

Between 2022 and 2024, the FDA-listed tirzepatide shortage created a legal opening for 503A compounding pharmacies to supply non-branded tirzepatide preparations. Large telehealth platforms grew up around that opening.

That opening closed. The FDA removed tirzepatide from the drug shortage list in October 2024, following Eli Lilly’s Sixth Circuit litigation against compounding pharmacies. The legal basis for routine 503A compounding of tirzepatide is gone. As of 2026, the FDA treats compounded tirzepatide as enforcement-priority illegal.

What that means for a patient in 2026:

• Any product sold today as “compounded tirzepatide” is either mislabeled, counterfeit, or dispensed under a 503B outsourcing-facility carve-out that no longer exists for tirzepatide.
• Telehealth vendors that continued to sell compounded tirzepatide after October 2024 are operating outside current FDA enforcement priorities.
• The price gap that drove the compounded market is largely closed, because LillyDirect Zepbound vials now sit in the same $349–$649/month range that compounded tirzepatide once occupied — but with a fully FDA-approved product, a licensed clinician prescription, and a partner-pharmacy shipping chain.

The full history is covered in the compounded semaglutide and tirzepatide safety pillar.

Which one should you ask your prescriber for in 2026?

Use this decision tree as a starting point for the conversation. Your prescriber will weigh other factors (comorbidities, prior response, cost sensitivity, plan formulary), but this maps the four most common situations.

• Type 2 diabetes with HbA1c ≥6.5% → ask for Mounjaro. Covered by commercial insurance and Medicare Part D. Delivers the weight-loss benefit of tirzepatide as a byproduct of glycemic treatment.
• Obesity without T2D, commercial insurance → ask for Zepbound. On-label for chronic weight management, covered by roughly 30–40% of commercial plans in 2026 with prior authorization, and eligible for the Zepbound savings card. If you also have moderate-to-severe OSA, that is a second on-label indication that can help coverage.
• Medicare Part D beneficiary, no T2D and no OSA → Zepbound cash-pay via LillyDirect vials. $349–$649/month depending on dose, and materially below the pen list price. Requires a US clinician prescription; ships through the LillyDirect partner pharmacy.
• Both T2D and obesity → ask for Mounjaro. Coverage is almost always easier under the T2D indication than under the obesity indication, and the weight-loss benefit is the same molecule at the same dose. Some clinicians will still write Zepbound if the patient’s plan happens to cover it more generously for obesity than for T2D — a call worth having with the benefits desk before the visit.

For pathway-level detail across the full prescription weight-loss landscape, see the prescription weight-loss medications hub.

What both drugs do not do

Neither Mounjaro nor Zepbound is a standalone weight-loss cure. Both replace part of the appetite pressure that drives calorie intake, but they do not replace the lifestyle work that determines what happens after the medication is stopped.

• Not a substitute for lifestyle intervention. Weight regain of 50–70% of lost weight within 12 months of drug discontinuation is documented across the class — Wilding et al. (STEP-4 semaglutide withdrawal, JAMA, 2021) and Aronne et al. (SURMOUNT-4 tirzepatide withdrawal, JAMA, 2024) show the same pattern. Structured maintenance calories, higher protein intake, and resistance training blunt but do not eliminate the rebound.
• Not for type 1 diabetes. Tirzepatide is not indicated for T1D and can produce dangerous hypoglycemia when combined with basal-bolus insulin regimens without careful dose adjustment.
• Not for pediatric use. Zepbound has adolescent SURMOUNT-Adolescents data, but the current 2026 label is 18+. Mounjaro is also adult-only.
• Not during pregnancy or breastfeeding. Both are contraindicated. Effective contraception is recommended for at least four weeks after the last dose before attempting conception.
• Not a short course. Both are chronic therapies. See the rebound weight gain after stopping GLP-1 pillar for what a taper conversation looks like when discontinuation is unavoidable — plan finalization, coverage loss, or pregnancy planning.

Frequently asked questions

Are Mounjaro and Zepbound the same drug? Yes. Both are tirzepatide, manufactured by Eli Lilly, in identical single-dose weekly pens at the same six strengths (2.5, 5, 7.5, 10, 12.5, and 15 mg). The molecule, dose range, side-effect profile, and dose escalation schedule are all the same. What differs is the FDA-approved indication on the label — Mounjaro for type 2 diabetes, Zepbound for chronic weight management and moderate-to-severe obstructive sleep apnea in adults with obesity — and how insurance and cash-pay programs treat each brand.

Which is cheaper — Mounjaro or Zepbound? In 2026, Zepbound is the cheaper cash-pay option because Eli Lilly’s LillyDirect self-pay program sells Zepbound single-dose vials from roughly $349 to $649 per month depending on dose. Mounjaro has no equivalent direct-to-consumer vial program. Auto-injector pen list prices are close (Mounjaro ~$1,080/month, Zepbound ~$1,060/month), so with insurance the two are effectively interchangeable on price; without insurance, Zepbound via LillyDirect is materially cheaper.

Can I use Mounjaro for weight loss if I don’t have diabetes? Some clinicians prescribe Mounjaro off-label for weight loss when Zepbound is not covered, but insurance almost never covers off-label Mounjaro without a documented type 2 diabetes diagnosis. If your goal is weight loss and you do not have T2D, the on-label pathway is Zepbound. Either way you are taking the same molecule at the same dose — the choice is a coverage and access decision, not a clinical one.

Does Medicare cover Mounjaro or Zepbound? Medicare Part D covers Mounjaro for type 2 diabetes with a documented HbA1c ≥6.5%. Medicare Part D does not cover Zepbound for weight loss alone — the federal Part D obesity-drug exclusion still stands in 2026. The December 2024 Zepbound label expansion for moderate-to-severe obstructive sleep apnea in adults with obesity is the narrow current lever for Part D coverage of Zepbound. For patients with neither T2D nor OSA, the LillyDirect vial program is the current lowest-friction pathway.

Can I switch from Mounjaro to Zepbound? Yes, and the switch is dose-for-dose because the pens and molecule are identical: 5 mg Mounjaro equals 5 mg Zepbound, 15 mg equals 15 mg. Your prescriber writes for the new brand at the same numeric dose you were on and titration does not restart unless you have been off drug for more than about six weeks. Insurance step therapy may require a prior authorization for the change of brand, but not a re-titration.

Do Mounjaro and Zepbound have the same side effects? Yes. Because the molecule is the same, the safety profile is identical: nausea (~25–30% at 15 mg), diarrhea (~15%), constipation (~10%), and vomiting (~10%), with side effects most pronounced during dose escalation. Both share the class boxed warning for thyroid C-cell tumors based on rodent data, and both carry the same uncommon-but-serious risks of pancreatitis, gallbladder disease, and dehydration-related acute kidney injury.

Is compounded tirzepatide still legal in 2026? No. The FDA removed tirzepatide from its drug shortage list in October 2024, following resolution of Eli Lilly’s Sixth Circuit litigation. That ended the legal basis for routine 503A compounding of tirzepatide, and the FDA now treats compounded tirzepatide as enforcement-priority illegal. Any product marketed as compounded tirzepatide in 2026 is either mislabeled, counterfeit, or being dispensed under a carve-out that no longer applies to this molecule.

Is Zepbound better than Wegovy? By average weight loss, yes — SURMOUNT-1 showed roughly 21% mean weight loss on tirzepatide 15 mg over 72 weeks, versus about 15% on semaglutide 2.4 mg in STEP-1 over 68 weeks. SURMOUNT-5 later confirmed a head-to-head advantage for tirzepatide over semaglutide in adults with obesity. Zepbound also carries an FDA-approved indication for moderate-to-severe obstructive sleep apnea in adults with obesity, which Wegovy does not.

How this article was researched

This article draws on the SURMOUNT and SURPASS phase 3 trial programs (published in NEJM, Lancet, and JAMA), the FDA prescribing information for Mounjaro and Zepbound, the FDA Drug Shortage database for the October 2024 tirzepatide status change, and publicly available Eli Lilly LillyDirect Self-Pay Pharmacy pricing. Coverage details reflect 2026-Q2 US commercial and Medicare Part D formulary norms and will move; confirm specific numbers with your insurer, clinician, or manufacturer before making a decision.